Erik Berntorp
11 – 20 of 329
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Alternative payment models for durable and potentially curative therapies : The case of gene therapy for haemophilia A
(
- Contribution to journal › Article
-
Mark
Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81–8973
(
- Contribution to journal › Article
-
Mark
Sixth Åland Island Conference on von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications
(
- Contribution to journal › Article
- 2021
-
Mark
A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa
(
- Contribution to journal › Article
-
Mark
Treatment outcomes in persons with severe haemophilia B in the Nordic region : The B-NORD study
(
- Contribution to journal › Article
-
Mark
In response to WFH guidelines for the management of haemophilia, 3rd edition : Is there a difference between extended-half-life FVIII products or not?
(
- Contribution to journal › Letter
-
Mark
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural)
(
- Contribution to journal › Article
-
Mark
Optimising prophylaxis in haemophilia A : The ups and downs of treatment
(
- Contribution to journal › Scientific review
-
Mark
Translating the success of prophylaxis in haemophilia to von Willebrand disease
(
- Contribution to journal › Scientific review